Top Page
Chimeric Therapeutics Ltd.
(Sydney:CHM)
Chimeric Therapeutics Ltd. (CHM) vs. iShares MSCI Australia ETF (EWA)
Chimeric Therapeutics Ltd. Business Overview & Revenue Model
Chimeric Therapeutics Ltd. Financial Statement Overview
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 9.12M | 3.97M | 7.46M | 0.00 | 2.62M | 2.65K |
| Gross Profit | 8.70M | 3.12M | 7.45M | 3.54M | 1.67M | -844.31K |
| EBITDA | -7.37M | -9.08M | -11.30M | -28.59M | -13.62M | -14.26M |
| Net Income | -6.64M | -10.43M | -12.53M | -25.92M | -15.90M | -15.11M |
Balance Sheet | ||||||
| Total Assets | 21.57M | 21.57M | 15.27M | 22.38M | 34.88M | 36.50M |
| Cash, Cash Equivalents and Short-Term Investments | 5.76M | 5.76M | 3.05M | 5.37M | 18.38M | 22.41M |
| Total Debt | 0.00 | 0.00 | 3.59M | 0.00 | 0.00 | 0.00 |
| Total Liabilities | 19.60M | 19.60M | 12.80M | 16.71M | 9.17M | 11.37M |
| Stockholders Equity | 1.97M | 1.97M | 2.47M | 5.66M | 25.71M | 25.13M |
Cash Flow | ||||||
| Free Cash Flow | -4.96M | -7.28M | 10.11K | -16.43M | -13.69M | -14.15M |
| Operating Cash Flow | -4.96M | -7.28M | -7.54M | -16.32M | -13.15M | -8.84M |
| Investing Cash Flow | 0.00 | 0.00 | 0.00 | -112.19K | -577.86K | -5.30M |
| Financing Cash Flow | 10.05M | 10.05M | 8.26M | 253.38K | 9.50M | 36.54M |
Chimeric Therapeutics Ltd. Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
50 Neutral | AU$92.53M | -9.67 | -49.72% | ― | ― | 10.78% | |
46 Neutral | AU$26.59M | -5.45 | -157.93% | ― | ― | -36.89% | |
45 Neutral | AU$8.84M | ― | -469.35% | ― | ― | 46.28% | |
44 Neutral | AU$9.02M | -17.46 | -8.72% | ― | ― | 71.10% | |
44 Neutral | AU$196.64M | -7.44 | ― | ― | ― | 0.66% | |
44 Neutral | AU$108.11M | -12.79 | -47.98% | ― | 700.00% | 26.88% |
Chimeric Therapeutics Ltd. Corporate Events
Chimeric Therapeutics Limited has announced a proposed capital raising via a placement and related securities issue, seeking to issue up to 690,099,278 new fully paid ordinary shares, 4,000,000 convertible notes, and a substantial number of options expiring in 2029 and 2030. The transaction, slated for completion around 11 March 2026, would significantly expand the company’s capital base and provide additional funding flexibility, potentially diluting existing shareholders but strengthening its financial position to support ongoing operations and future growth initiatives.
Chimeric Therapeutics Limited has notified the market of the issue of 16,667,000 unquoted options under an employee incentive scheme, with various exercise prices and expiry dates, effective 12 December 2025. The additional unquoted equity securities expand the company’s pool of staff incentives, aligning employee remuneration with shareholder interests and potentially impacting future capital structure depending on option exercise and subsequent share issuance.
Chimeric Therapeutics has disclosed a change in director Miles Prince’s interests, confirming the issue of 16,667,000 unlisted options to him following shareholder approval at the company’s 25 November 2025 Annual General Meeting. The grant, made for nil cash consideration and without any disposal of existing securities, increases Prince’s direct exposure to the company’s equity and further aligns his incentives with shareholders, signalling continued confidence in Chimeric’s strategic direction in the competitive oncology biotech space.
Chimeric Therapeutics has requested and been granted a trading halt on its securities by the ASX as it prepares to announce details of a material capital raising. The halt will remain in place until the anticipated announcement is released or until the start of normal trading on 23 December 2025, signalling that the company is undertaking a significant funding initiative that could influence its capital structure and near-term strategic activities.
Chimeric Therapeutics announced that its novel CAR-T cell therapy, CHM 1107, has been granted Orphan Drug Designation by the FDA for the treatment of gastric cancer. This designation provides the company with incentives such as tax credits and potential market exclusivity, enhancing its position in the cell therapy industry and addressing significant unmet medical needs in gastric cancer treatment.
Chimeric Therapeutics announced significant board changes following shareholder feedback from its recent AGM, including the appointment of a new Chairperson and a Non-Executive Director nominated by a major shareholder. The company is optimistic about its future as it progresses its CHM CDH17 Phase 1/2 trial, which is showing promising results in tumor shrinkage and disease control, with more data expected soon.
Chimeric Therapeutics Ltd. announced the resignation of Paul Hopper from his position as a director, effective November 25, 2025. This change in the board may impact the company’s strategic direction and investor confidence, given Hopper’s significant holdings of 21,232,142 ordinary shares and 31,580,882 options. The transition could influence the company’s operations and its positioning in the competitive biotechnology market.
Chimeric Therapeutics Ltd. announced the results of its Annual General Meeting, where all resolutions were conducted via poll. A significant outcome was the ‘first strike’ against the Remuneration Report under the Corporations Act, indicating shareholder dissatisfaction with executive pay. Additionally, Paul Hopper retired as Executive Chairman, with Phillip Hains appointed as Acting Chair until a new Chair is announced. The meeting also saw the election of Professor Henry Miles Prince as a Director and approval for issuing incentive options to him, while similar options for Paul Hopper were not approved. These developments may impact the company’s governance and strategic direction.
Chimeric Therapeutics Ltd. has issued a news release containing forward-looking statements, highlighting potential risks and uncertainties related to their clinical trials and regulatory approvals. The announcement underscores the company’s commitment to advancing its cell therapy solutions while acknowledging the challenges and costs associated with clinical trials and regulatory processes.
Chimeric Therapeutics has received a $4.5 million R&D tax incentive from the Australian Government, recognizing its research and development activities in 2025. This financial boost supports Chimeric’s ongoing efforts in advancing its cell therapy programs, potentially enhancing its position in the oncology treatment market and benefiting stakeholders through continued innovation in cancer therapies.
Chimeric Therapeutics announced promising results from its CHM CDH17 Phase 1/2 clinical trial, showing 75% disease control among evaluable subjects at 28 days. The trial, which focuses on advanced colorectal cancer, gastric cancer, and gastrointestinal NETs, demonstrated stable disease in all patients treated at Dose Level 2, with one patient maintaining stable disease for nearly a year without additional therapy. This progress underscores the potential impact of CHM CDH17 as a novel CAR-T cell therapy targeting CDH17, a biomarker linked to poor prognosis in gastrointestinal tumors.
Chimeric Therapeutics has temporarily suspended its CHM CORE-NK + Vactosertib Phase 1b clinical trial due to supply chain issues unrelated to the treatment itself. The trial aims to treat patients with advanced colorectal and blood cancers, and the company expects to resolve the issue soon, potentially impacting its operations and stakeholder confidence.
Chimeric Therapeutics Limited responded to an ASX query regarding the ADVENT-AML clinical trial results. The company disclosed that no dose-limiting toxicities were observed, and CORE-NK cells persisted in patients’ blood. Notably, 57% of high-risk frontline subjects showed clinical responses, with two new complete responses in AML. This information, although not initially disclosed, is considered to have a potential material impact on the company’s securities when combined with additional new data.
Chimeric Therapeutics has reported significant progress in its CHM CDH17 Phase 1/2 clinical trial, advancing to dose level 2 with promising safety and efficacy results. The trial has shown manageable safety profiles and encouraging disease control in patients, with notable tumor size reductions in colorectal and neuroendocrine cancers. Additionally, the company has strengthened its leadership by appointing Professor Miles Prince as a Non-Executive Director and has signed a local manufacturing agreement with the New South Wales Government, potentially enhancing its operational capabilities.
Chimeric Therapeutics Ltd. has announced the issuance of new unquoted equity securities, including 387,577,500 options expiring in March 2026 and 25,000,000 options expiring in October 2028. This move is part of a previously announced transaction, reflecting the company’s strategic efforts to bolster its financial position and support its ongoing research and development initiatives.
Chimeric Therapeutics Ltd. has announced the quotation of 387,577,500 fully paid ordinary securities on the Australian Securities Exchange (ASX). This move is part of previously announced transactions, potentially enhancing the company’s financial flexibility and market presence, which could have significant implications for its growth strategy and stakeholder engagement.
Chimeric Therapeutics Ltd. has issued a disclaimer regarding forward-looking statements in their presentation, highlighting potential risks and uncertainties that could impact their clinical trials and regulatory approvals. The company emphasizes the unpredictability of clinical trial outcomes and the possibility of additional regulatory requirements, advising stakeholders to exercise caution in relying on these projections.
Chimeric Therapeutics announced an investor webinar to discuss clinical updates from its CHM CDH17 and CHM CORE-NK programs. These programs are part of Chimeric’s efforts to advance its cell therapy portfolio, which shows promise in treating various cancers. The webinar aims to provide stakeholders with insights into the progress and future directions of these therapies, potentially impacting the company’s market positioning and stakeholder interests.
Chimeric Therapeutics announced promising results from its ADVENT-AML Phase 1B clinical trial, showcasing new clinical and translational data at the Society of Hematology Oncology Annual Meeting. The trial, which focuses on treating relapsed or refractory AML patients with CORE-NK cell therapy in combination with standard AML treatments, reported a 57% clinical response rate among high-risk frontline subjects. The trial has demonstrated safety and efficacy, with no dose-limiting toxicities observed, and is now expanding to include newly diagnosed AML patients who are ineligible for intensive chemotherapy. This development underscores Chimeric’s commitment to advancing cell therapy and could significantly impact treatment options for AML patients.